Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
37 hedge funds and large institutions have $39.8M invested in Genocea Biosciences, Inc. in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 11 increasing their positions, 10 reducing their positions, and 12 closing their positions.
480,200% more call options, than puts
Call options by funds: $4.8M | Put options by funds: $1K
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
18% less funds holding
Funds holding: 45 → 37 (-8)
31% less capital invested
Capital invested by funds: $57.4M → $39.8M (-$17.6M)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$407K |
| 2 |
FIA
FNY Investment Advisers
New York
|
+$405K |
| 3 |
BlackRock
New York
|
+$160K |
| 4 |
Renaissance Technologies
New York
|
+$126K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$99.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.46M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$655K |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$392K |
| 4 |
VF
Virtu Financial
New York
|
-$363K |
| 5 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$347K |
GNCA Hedge Fund Activity: Q3 2019 in Review
37 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q3 2019, worth a combined $39.8M — down 31% from $57.4M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GNCA and 4 opened new positions — a net loss of 8 holders — while 10 trimmed existing stakes and 11 added.
The largest buyer was Geode Capital Management, adding an estimated $407K. The largest seller was Vivo Capital, exiting entirely with an estimated $2.46M sold.
- 37 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q3 2019, down from 45 in Q2 2019.
- Funds reported $39.8M of Genocea Biosciences, Inc. stock for Q3 2019, down 31% quarter-over-quarter.
- 4 funds opened new Genocea Biosciences, Inc. positions in Q3 2019 and 12 closed out, a net change of -8 holders.
- The largest Genocea Biosciences, Inc. buyer in Q3 2019 was Geode Capital Management, an estimated $407K added.
- The largest Genocea Biosciences, Inc. seller in Q3 2019 was Vivo Capital, an estimated $2.46M sold.
Based on aggregated 13F filings for Q3 2019.